share_log

B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target

B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target

A股银行将Beam Therapeutics的评级下调至中性,宣布35美元的目标股价
Benzinga ·  2023/12/15 08:37

B of A Securities analyst Greg Harrison downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and announces $35 price target.

Bof A证券分析师格雷格·哈里森将Beam Therapeutics(纳斯达克股票代码:BEAM)的评级从买入下调至中性,并宣布了35美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发